Evidence map›Paper›PMID 36120594›Full record

ArticleOxidative medicine and cellular longevity2022

miR-342-3p Inhibits Acute Myeloid Leukemia Progression by Targeting SOX12.

Ying Wang, Xiaonan Guo, Lihua Wang, Lina Xing, Xiaolei Zhang, Jinhai Ren

Open access · hybridAbstract read
In one paragraph

Article in Oxidative medicine and cellular longevity, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Ying WangDepartment of Hematology, The Second Hospital of Hebei Medical University, Shijiazhuang, 050000 Hebei, China.
Xiaonan GuoDepartment of Hematology, The Second Hospital of Hebei Medical University, Shijiazhuang, 050000 Hebei, China.
Lihua WangDepartment of Hematology, The Second Hospital of Hebei Medical University, Shijiazhuang, 050000 Hebei, China.
Lina XingDepartment of Hematology, The Second Hospital of Hebei Medical University, Shijiazhuang, 050000 Hebei, China.
Xiaolei ZhangDepartment of Hematology, The Second Hospital of Hebei Medical University, Shijiazhuang, 050000 Hebei, China.
Jinhai RenDepartment of Hematology, The Second Hospital of Hebei Medical University, Shijiazhuang, 050000 Hebei, China.ORCID https://orcid.org/0000-0001-7532-0963
Hebei Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: It is well known that microRNAs (miRNAs) interfere with the progression of various human malignancies. This article is aimed at exploring the regulating role of miR-342-3p in acute myeloid leukemia (AML) and its mechanism. Methods: We used the Gene Expression Omnibus (GEO) database to determine miR-342-3p differential expression patterns in AML patients' plasma and cells as well as healthy individuals' plasma and T cells. Quantitative real-time PCR and Western blotting were performed for plasma and cell miR-342-3p and SRY-related high-mobility-group box (SOX12) expression quantification, and cell counting kit-8 assay and flow cytometry were used for the determination of AML cell growth, cycle, and apoptosis. A dual-luciferase reporter gene assay was further carried out to identify the targeted association between miR-342-3p and SOX12 mRNA 3'UTR after prediction by a bioinformatics website. Pearson's correlation analysis was performed to analyze the connection between miR-342-3p and SOX12 expressions. The LinkedOmics database was utilized to explore the downstream pathways in which SOX12 was enriched. Results: Evidently downregulated plasma miR-342-3p and markedly elevated SOX12 were observed in AML patients versus healthy individuals. miR-342-3p mimics suppressed AML cell growth, enhanced apoptosis, and induced G0/G1 phase arrest; conversely, enhanced capacity of AML cells to proliferate, suppressed apoptosis, and accelerated cell cycle were observed after treatment with miR-342-3p inhibitors. SOX12 was confirmed as miR-342-3p's target gene. Overexpressing or knocking down SOX12 reversed miR-342-3p's impacts on AML cell growth, apoptosis, and cycle. Upregulated SOX12 was positively related to DNA replication and RNA polymerase signaling pathways. Conclusion: miR-342-3p affects apoptosis of AML cells and their ability to proliferate via targeted regulation of SOX12.

Indexed as

Leukemia, Myeloid, AcuteMicroRNAs3' Untranslated RegionsCell Line, TumorHumansLuciferasesRNA, MessengerSOXC Transcription Factors3' Untranslated RegionsLuciferasesMicroRNAsMIRN342 microRNA, humanRNA, MessengerSOX12 protein, humanSOXC Transcription Factors

Identifiers

PMID36120594
PMCPMC9477626
OpenAlexW4295181331

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.